The commonly reported events in both the treatment groups were pyrexia (DA-α vs. EPO: 9.5% vs. 7.9%), cough (9.5% vs. 15.9%), vomiting (4.8% vs. 6.3%), nasopharyngitis (4.8% vs. 6.3%), increased blood creatinine and urea (4.8% vs. 4.8% for each) and decreased glomerular filtration rate (4.8% vs. 4.8%). This evidence concerns the gene EPO and Fever.